Jeremy Chadwick Sells 4,279 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 4,279 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $81.58, for a total value of $349,080.82. Following the completion of the sale, the chief operating officer owned 44,018 shares in the company, valued at $3,590,988.44. This trade represents a 8.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Trading Down 0.3%

NASDAQ KYMR opened at $81.46 on Friday. The business’s 50-day moving average price is $83.29 and its two-hundred day moving average price is $79.30. Kymera Therapeutics, Inc. has a 12 month low of $28.50 and a 12 month high of $103.00. The firm has a market capitalization of $6.70 billion, a PE ratio of -22.82 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. During the same quarter in the previous year, the company posted ($0.82) EPS. The business’s revenue was up 55.5% on a year-over-year basis. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Glenmede Trust Co. NA lifted its stake in shares of Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after purchasing an additional 235 shares during the period. Amundi acquired a new position in shares of Kymera Therapeutics in the 1st quarter valued at about $249,000. California State Teachers Retirement System raised its stake in Kymera Therapeutics by 23.0% during the 1st quarter. California State Teachers Retirement System now owns 56,282 shares of the company’s stock worth $4,688,000 after buying an additional 10,540 shares during the period. Eagle Health Investments LP raised its stake in Kymera Therapeutics by 7.0% during the 1st quarter. Eagle Health Investments LP now owns 145,816 shares of the company’s stock worth $12,145,000 after buying an additional 9,516 shares during the period. Finally, Empowered Funds LLC acquired a new position in Kymera Therapeutics during the 1st quarter worth approximately $203,000.

Analysts Set New Price Targets

A number of equities research analysts have commented on KYMR shares. Jefferies Financial Group started coverage on Kymera Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $110.00 price target on the stock. Morgan Stanley reissued an “overweight” rating and issued a $119.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Citigroup boosted their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Canaccord Genuity Group initiated coverage on Kymera Therapeutics in a research note on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.